{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-010868","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.685935+00:00","generated_at":"2026-05-24T12:22:20.400189+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Telomir-1 reduces tumor size ~50% in prostate cancer model; protects against chemo toxicity","bullets":["Telomir-1 alone (low and high doses) reduced tumor growth ~50% in aggressive human prostate cancer animal model.","Contrary to concerns, Telomir-1 suppressed tumor development and selectively benefited healthy cells.","Paclitaxel alone caused severe toxicity with one-third mortality; adding low-dose Telomir-1 eliminated mortality.","Telomir-1 combined with Paclitaxel neutralized chemotherapy-induced toxicity and weight loss.","Results position Telomir-1 as a potential adjunct to standard chemotherapy for prostate cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-010868","json":"https://secwatch.observer/filing/0001493152-25-010868.json","markdown":"https://secwatch.observer/filing/0001493152-25-010868.md","text":"https://secwatch.observer/filing/0001493152-25-010868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225010868/0001493152-25-010868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225010868/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T12:22:20.400189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}